ALLOPURINOL (allopurinol) by Teva is xanthine oxidase inhibitors [moa]. Approved for gout, hyperuricemia. First approved in 1984.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
Allopurinol is an oral xanthine oxidase inhibitor approved in 1984 for treating gout and hyperuricemia by reducing serum uric acid production. It works by inhibiting the enzyme xanthine oxidase, which catalyzes the final steps of purine metabolism, thereby lowering uric acid levels in the blood and urine.
With LOE approaching and modest annual spending of $15M, the brand team is likely in consolidation mode focused on defending market share against generic erosion and newer therapeutic alternatives.
Xanthine Oxidase Inhibitors
Xanthine Oxidase Inhibitor
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
Worked on ALLOPURINOL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on allopurinol offers limited upside growth potential given its LOE-approaching status and mature market position, but provides stable, established-product management experience valuable for pharma professionals. Roles are primarily focused on defending market share, managing generic competition, and optimizing commercial operations rather than growth or innovation.